Overview

Smoking-related diseases kill more Americans than alcohol, illegal drugs, murder and suicide combined. The passage of the Family Smoking Prevention and Tobacco Control Act of 2009 gave the FDA authority to regulate ""modified risk tobacco products"" (MRTPs), tobacco products that are either designed or advertised to reduce harm or the risk of tobacco-related disease. MRTPs must submit to the FDA scientific evidence to demonstrate the product has the potential to reduce tobacco related harms as compared to conventional tobacco products. The IOM identifies minimum standards for scientific studies that an applicant would need to complete to obtain an order to market the product from the FDA. Table of Contents Front Matter Summary 1 Introduction 2 Governance and Conduct of Studies 3 Evidence Base and Methods for Studying Health Effects 4 Methods for Investigating Addictive Potential 5 Methods for Studying Risk Perception and Risk Communication 6 Decision Making and Oversight of MRTP Studies: Findings and Recommendations Appendix A: Section 911 of the Family Smoking Prevention and Tobacco Control Act of 2009 Appendix B: Chapters 1 and 2 from *Evaluation of Biomarkers andSurrogate Endpoints in Chronic Disease* [Appendix B] 1 Introduction [Appendix B] 2 Review: Evaluating and Regulating Biomarker Use Appendix C: Committee Biographies Appendix D: Meeting Agendas

Full Product Details

9780309223980

Table of Contents

Reviews

Author Information

Tab Content 6

Customer Reviews

Recent Reviews

Countries Available